SEC Form 4 · accession 0001209191-17-012427
Phio Pharmaceuticals Corp. · PHIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Geert Cauwenbergh
Officer — President & CEO · Director
Period of report
Feb 17, 2017
Accepted (ET)
Feb 21, 2017 · 7:11 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001533040
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock, $0.0001 par value | Feb 17, 2017 | P | 200 | $0.6915 | A | 82,783 | D | |
| Common stock, $0.0001 par value | Feb 17, 2017 | P | 6,883 | $0.6924 | A | 89,666 | D | |
| Common stock, $0.0001 par value | Feb 17, 2017 | P | 2,917 | $0.695 | A | 92,583 | D | |
| Common stock, $0.0001 par value | holding | — | — | — | 4,500 | I | By spouse | |
| Common stock, $0.0001 par valueF1 | holding | — | — | — | 450 | I | By son |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares held by the Reporting Person's son. The Reporting Person disclaims beneficial ownership of such shares and this report shall not constitute an admission of beneficial ownership.